In a patient with asthma and chronic rhinosinusitis with nasal polyps who has not responded to benralizumab (Fasenra) for nasal polyps, what are the differences between mepolizumab (Nucala) and benralizumab regarding efficacy in this indication?

Switch to Mepolizumab for CRSwNP Non-Response to Benralizumab

In a patient with asthma and CRSwNP who has not responded to benralizumab for nasal polyps, switching to mepolizumab is a reasonable therapeutic option, though the evidence base for mepolizumab in CRSwNP is significantly stronger than for benralizumab.

Key Mechanistic Differences

The fundamental difference lies in their mechanism of action within the IL-5 pathway:

• Benralizumab blocks the IL-5 receptor alpha (IL-5Rα) on eosinophils and basophils, inducing rapid apoptosis through antibody-dependent cell-mediated cytotoxicity (ADCC) 1
• Mepolizumab binds free circulating IL-5, preventing it from binding to its receptor 1

While both deplete eosinophils, benralizumab achieves near-complete depletion more rapidly, whereas mepolizumab reduces but does not eliminate eosinophils 2.

Evidence Quality: A Critical Distinction

The most important difference is the level of evidence supporting each drug for CRSwNP:

Mepolizumab Evidence (Strong)

• FDA-approved specifically for CRSwNP in adults ≥18 years with inadequate response to nasal corticosteroids 3
• Two robust placebo-controlled trials demonstrated efficacy 1:
  • Bachert 2017 (n=105): 30% of mepolizumab patients no longer needed surgery vs 10% placebo (p=0.006); significant improvements in VAS scores for rhinorrhea, nasal blockage, mucus, and smell loss; SNOT-22 improved by -13.2 points 1
  • Gevaert 2011 (n=30): Significant polyp score reduction (-1.3, p=0.028); 60% vs 10% improvement rate 1
• Real-world data confirms efficacy across comorbidities including asthma and AERD 4, 5
• EPOS 2020 guideline explicitly recommends mepolizumab for CRSwNP patients meeting biologic criteria 1

Benralizumab Evidence (Limited)

• NOT FDA-approved for CRSwNP 1
• EPOS 2020 states "RCT studies on benralizumab, a blocker of IL-5Rα, are ongoing" 1
• Evidence limited to:
  • One small RCT (n=24): showed statistically significant polyp reduction vs baseline (p=0.004) but not vs placebo (p=0.103) 6
  • Real-world observational studies showing benefit in comorbid asthma/CRSwNP patients 7, 8
• Current guidelines do not recommend benralizumab for CRSwNP as primary indication 9, 10

Clinical Efficacy Comparison

Mepolizumab Performance in CRSwNP

• Reduces need for surgery by 20% absolute risk reduction 1
• Improves nasal obstruction, rhinorrhea, and smell loss 1
• Effective regardless of baseline eosinophil count (<150 or ≥150 cells/μL) 4
• Works in both allergic and non-allergic patients 1
• Benefits maintained with asthma and AERD comorbidities 4, 5

Benralizumab Performance in CRSwNP

• Real-world studies show improvements in SNOT-22, nasal polyp scores, and nasal cytology 8
• 42% of patients showed improvement in all outcomes (polyp score, CT, SNOT-22, smell) vs 17% placebo 6
• May be more effective in "exacerbation-dominant" eosinophilic phenotype 11
• Benefits appear primarily in patients with concomitant severe eosinophilic asthma 7, 8

Why Your Patient May Not Have Responded to Benralizumab

Several factors may explain lack of CRSwNP response:

1. Off-label use: Benralizumab lacks regulatory approval and robust trial data for CRSwNP as primary indication
2. Phenotype mismatch: May be less effective in "sinonasal-dominant" phenotype vs "exacerbation-dominant" asthma phenotype 11
3. Insufficient treatment duration: Real-world studies typically show benefits after 6-12 months 8
4. Non-eosinophilic endotype: Though less likely given asthma comorbidity

Practical Switching Strategy

When switching from benralizumab to mepolizumab:

• Dosing: Mepolizumab 100 mg subcutaneous every 4 weeks 3
• Timing: Can switch immediately; no washout period required given different mechanisms
• Monitoring timeframe: Assess response at 6 months (polyp score, SNOT-22, VAS symptoms) 1, 5
• Expected outcomes:
  • 30% chance of avoiding surgery 1
  • Significant SNOT-22 improvement (mean -13.2 points) 1
  • Polyp size reduction in 50-60% of patients 1, 4

Important Caveats

• Both drugs require continued intranasal corticosteroids as standard of care 9, 10
• Consider whether patient has had adequate endoscopic sinus surgery; guidelines recommend surgery before biologics in surgical candidates 9
• If mepolizumab also fails, dupilumab (anti-IL-4/IL-13) is FDA-approved for CRSwNP and may target different inflammatory pathways 1, 9
• Neither drug works for acute symptoms; both are maintenance therapy 3

The evidence strongly favors mepolizumab as the appropriate anti-IL-5 therapy for CRSwNP 1, 3, making it the logical next step after benralizumab failure in this indication.